Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

T. Powles, P. Tomczak, SH. Park, B. Venugopal, T. Ferguson, SN. Symeonides, J. Hajek, H. Gurney, YH. Chang, JL. Lee, N. Sarwar, A. Thiery-Vuillemin, M. Gross-Goupil, M. Mahave, NB. Haas, P. Sawrycki, JE. Burgents, L. Xu, K. Imai, DI. Quinn, TK....

. 2022 ; 23 (9) : 1133-1144. [pub] -

Language English Country England, Great Britain

Document type Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc22024633
E-resources Online Full text

NLK ProQuest Central from 2000-09-01 to 2 months ago
Nursing & Allied Health Database (ProQuest) from 2000-09-01 to 2 months ago
Health & Medicine (ProQuest) from 2000-09-01 to 2 months ago
Public Health Database (ProQuest) from 2000-09-01 to 2 months ago

Links

PubMed 36055304
DOI 10.1016/s1470-2045(22)00487-9
Knihovny.cz E-resources

BACKGROUND: The first interim analysis of the KEYNOTE-564 study showed improved disease-free survival with adjuvant pembrolizumab compared with placebo after surgery in patients with clear cell renal cell carcinoma at an increased risk of recurrence. The analysis reported here, with an additional 6 months of follow-up, was designed to assess longer-term efficacy and safety of pembrolizumab versus placebo, as well as additional secondary and exploratory endpoints. METHODS: In the multicentre, randomised, double-blind, placebo-controlled, phase 3 KEYNOTE-564 trial, adults aged 18 years or older with clear cell renal cell carcinoma with an increased risk of recurrence were enrolled at 213 hospitals and cancer centres in North America, South America, Europe, Asia, and Australia. Eligible participants had an Eastern Cooperative Oncology Group performance status of 0 or 1, had undergone nephrectomy 12 weeks or less before randomisation, and had not received previous systemic therapy for advanced renal cell carcinoma. Participants were randomly assigned (1:1) via central permuted block randomisation (block size of four) to receive pembrolizumab 200 mg or placebo intravenously every 3 weeks for up to 17 cycles. Randomisation was stratified by metastatic disease status (M0 vs M1), and the M0 group was further stratified by ECOG performance status and geographical region. All participants and investigators involved in study treatment administration were masked to the treatment group assignment. The primary endpoint was disease-free survival by investigator assessment in the intention-to-treat population (all participants randomly assigned to a treatment). Safety was assessed in the safety population, comprising all participants who received at least one dose of pembrolizumab or placebo. As the primary endpoint was met at the first interim analysis, updated data are reported without p values. This study is ongoing, but no longer recruiting, and is registered with ClinicalTrials.gov, NCT03142334. FINDINGS: Between June 30, 2017, and Sept 20, 2019, 994 participants were assigned to receive pembrolizumab (n=496) or placebo (n=498). Median follow-up, defined as the time from randomisation to data cutoff (June 14, 2021), was 30·1 months (IQR 25·7-36·7). Disease-free survival was better with pembrolizumab compared with placebo (HR 0·63 [95% CI 0·50-0·80]). Median disease-free survival was not reached in either group. The most common all-cause grade 3-4 adverse events were hypertension (in 14 [3%] of 496 participants) and increased alanine aminotransferase (in 11 [2%]) in the pembrolizumab group, and hypertension (in 13 [3%] of 498 participants) in the placebo group. Serious adverse events attributed to study treatment occurred in 59 (12%) participants in the pembrolizumab group and one (<1%) participant in the placebo group. No deaths were attributed to pembrolizumab. INTERPRETATION: Updated results from KEYNOTE-564 support the use of adjuvant pembrolizumab monotherapy as a standard of care for participants with renal cell carcinoma with an increased risk of recurrence after nephrectomy. FUNDING: Merck Sharp & Dohme LLC, a subsidiary of Merck & Co, Inc, Rahway, NJ, USA.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22024633
003      
CZ-PrNML
005      
20221031100107.0
007      
ta
008      
221017s2022 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/S1470-2045(22)00487-9 $2 doi
035    __
$a (PubMed)36055304
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Powles, Thomas $u Royal Free Hospital NHS Foundation Trust, University College London, London, UK; Barts Cancer Institute, Experimental Cancer Medicine Centre, Queen Mary University of London, St Bartholomew's Hospital, London, UK. Electronic address: thomas.powles1@nhs.net
245    10
$a Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial / $c T. Powles, P. Tomczak, SH. Park, B. Venugopal, T. Ferguson, SN. Symeonides, J. Hajek, H. Gurney, YH. Chang, JL. Lee, N. Sarwar, A. Thiery-Vuillemin, M. Gross-Goupil, M. Mahave, NB. Haas, P. Sawrycki, JE. Burgents, L. Xu, K. Imai, DI. Quinn, TK. Choueiri, KEYNOTE-564 Investigators
520    9_
$a BACKGROUND: The first interim analysis of the KEYNOTE-564 study showed improved disease-free survival with adjuvant pembrolizumab compared with placebo after surgery in patients with clear cell renal cell carcinoma at an increased risk of recurrence. The analysis reported here, with an additional 6 months of follow-up, was designed to assess longer-term efficacy and safety of pembrolizumab versus placebo, as well as additional secondary and exploratory endpoints. METHODS: In the multicentre, randomised, double-blind, placebo-controlled, phase 3 KEYNOTE-564 trial, adults aged 18 years or older with clear cell renal cell carcinoma with an increased risk of recurrence were enrolled at 213 hospitals and cancer centres in North America, South America, Europe, Asia, and Australia. Eligible participants had an Eastern Cooperative Oncology Group performance status of 0 or 1, had undergone nephrectomy 12 weeks or less before randomisation, and had not received previous systemic therapy for advanced renal cell carcinoma. Participants were randomly assigned (1:1) via central permuted block randomisation (block size of four) to receive pembrolizumab 200 mg or placebo intravenously every 3 weeks for up to 17 cycles. Randomisation was stratified by metastatic disease status (M0 vs M1), and the M0 group was further stratified by ECOG performance status and geographical region. All participants and investigators involved in study treatment administration were masked to the treatment group assignment. The primary endpoint was disease-free survival by investigator assessment in the intention-to-treat population (all participants randomly assigned to a treatment). Safety was assessed in the safety population, comprising all participants who received at least one dose of pembrolizumab or placebo. As the primary endpoint was met at the first interim analysis, updated data are reported without p values. This study is ongoing, but no longer recruiting, and is registered with ClinicalTrials.gov, NCT03142334. FINDINGS: Between June 30, 2017, and Sept 20, 2019, 994 participants were assigned to receive pembrolizumab (n=496) or placebo (n=498). Median follow-up, defined as the time from randomisation to data cutoff (June 14, 2021), was 30·1 months (IQR 25·7-36·7). Disease-free survival was better with pembrolizumab compared with placebo (HR 0·63 [95% CI 0·50-0·80]). Median disease-free survival was not reached in either group. The most common all-cause grade 3-4 adverse events were hypertension (in 14 [3%] of 496 participants) and increased alanine aminotransferase (in 11 [2%]) in the pembrolizumab group, and hypertension (in 13 [3%] of 498 participants) in the placebo group. Serious adverse events attributed to study treatment occurred in 59 (12%) participants in the pembrolizumab group and one (<1%) participant in the placebo group. No deaths were attributed to pembrolizumab. INTERPRETATION: Updated results from KEYNOTE-564 support the use of adjuvant pembrolizumab monotherapy as a standard of care for participants with renal cell carcinoma with an increased risk of recurrence after nephrectomy. FUNDING: Merck Sharp & Dohme LLC, a subsidiary of Merck & Co, Inc, Rahway, NJ, USA.
650    _2
$a dospělí $7 D000328
650    _2
$a humanizované monoklonální protilátky $7 D061067
650    _2
$a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
650    12
$a karcinom z renálních buněk $x farmakoterapie $x chirurgie $7 D002292
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a následné studie $7 D005500
650    _2
$a lidé $7 D006801
650    12
$a hypertenze $7 D006973
650    12
$a nádory ledvin $x farmakoterapie $x etiologie $x chirurgie $7 D007680
650    _2
$a nefrektomie $x škodlivé účinky $7 D009392
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Tomczak, Piotr $u Poznań University of Medical Sciences, Poznań, Poland
700    1_
$a Park, Se Hoon $u Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
700    1_
$a Venugopal, Balaji $u Beatson West of Scotland Cancer Centre, Glasgow, UK; Institute of Cancer Sciences, University of Glasgow, Glasgow, UK
700    1_
$a Ferguson, Thomas $u Fiona Stanley Hospital, Perth, WA, Australia
700    1_
$a Symeonides, Stefan N $u Cancer Research UK Edinburgh Centre, Edinburgh, UK; Edinburgh Cancer Centre, Edinburgh, UK; Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK
700    1_
$a Hajek, Jaroslav $u Fakultní nemocnice Ostrava, Ostrava, Czech Republic
700    1_
$a Gurney, Howard $u Department of Clinical Medicine, Macquarie University, Sydney, NSW, Australia
700    1_
$a Chang, Yen-Hwa $u Taipei Veterans General Hospital, Taipei, Taiwan
700    1_
$a Lee, Jae Lyun $u Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
700    1_
$a Sarwar, Naveed $u Imperial College Healthcare NHS Trust, London, UK
700    1_
$a Thiery-Vuillemin, Antoine $u University Hospital Jean Minjoz, Besançon, France
700    1_
$a Gross-Goupil, Marine $u University Hospital Bordeaux-Hôpital Saint-André, Bordeaux, France
700    1_
$a Mahave, Mauricio $u Arturo López Pérez Foundation, Santiago, Chile
700    1_
$a Haas, Naomi B $u Abramson Cancer Center, Philadelphia, PA, USA
700    1_
$a Sawrycki, Piotr $u Wojewódzki Szpital Zespolony im L Rydygiera w Toruniu, Torun, Poland
700    1_
$a Burgents, Joseph E $u Merck & Co, Inc, Rahway, NJ, USA
700    1_
$a Xu, Lei $u Merck & Co, Inc, Rahway, NJ, USA
700    1_
$a Imai, Kentaro $u Merck & Co, Inc, Rahway, NJ, USA
700    1_
$a Quinn, David I $u USC Norris Comprehensive Cancer Center, Los Angeles, CA, USA
700    1_
$a Choueiri, Toni K $u Dana-Farber Cancer Institute, Boston, MA, USA
710    2_
$a KEYNOTE-564 Investigators
773    0_
$w MED00011558 $t Lancet oncology $x 1474-5488 $g Roč. 23, č. 9 (2022), s. 1133-1144
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36055304 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20221017 $b ABA008
991    __
$a 20221031100105 $b ABA008
999    __
$a ok $b bmc $g 1854393 $s 1175923
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 23 $c 9 $d 1133-1144 $e - $i 1474-5488 $m Lancet oncology $n Lancet Oncol. $x MED00011558
LZP    __
$a Pubmed-20221017

Find record

Citation metrics

Archiving options